—

Scholar Rock Holding Corp (SRRK) — the peer cohort

As of 2026-10-08 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Scholar Rock Holding Corp ranks 7 of 7 in its cohort on the Closelooknet composite (23/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
SRRK Scholar Rock Holding Corp 23 29 0 — info 31.7%
HALO Halozyme Therapeutics Inc 74 94 94 51 ok 6%
BION.SW BB Biotech AG 73 57 96 81 info 16.1%
ONC BeiGene, Ltd. 64 77 64 32 info 9.1%
KRYS Krystal Biotech Inc 60 62 85 20 info 14.4%
PTGX Protagonist Therapeutics Inc 60 79 61 11 info 13%
REGN Regeneron Pharmaceuticals Inc 60 60 71 52 bull 13.6%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-08

Quick answers

Who are Scholar Rock Holding Corp's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BB Biotech AG (BION.SW), BeiGene, Ltd. (ONC), Krystal Biotech Inc (KRYS), Protagonist Therapeutics Inc (PTGX), Regeneron Pharmaceuticals Inc (REGN).

How does SRRK score against its peers?

Scholar Rock Holding Corp's composite reads 23/100, ranking 7 of 7 in its cohort as of 2026-10-08; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.